Evotec Expands its 2016 Agreement with Bristol-Myers Squibb

Nosopharm Signs an Agreement with Evotec to Accelerate the Development of Antibiotics


  • Evotec to receive $6M payment from BMS to expand its partnership with the inclusion of additional cell lines
  • In 2016, Evotec signed a 5-year research agreement with Celgene (now a part of BMS) for the identification of therapies based on Evotec’s technology platforms in conjunction with the human iPSC- based platform for multiple neurodegenerative diseases
  •  iPSCs are adult cells genetically reprogrammed to an embryonic stem cell for expressing genes & properties of embryonic stem cells

Click here to read full press release/ article | Ref: Evotec | Image: Behance